Beyondspring (NASDAQ:BYSI) Upgraded at ValuEngine

Beyondspring (NASDAQ:BYSI) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, ValuEngine reports.

Several other equities research analysts also recently issued reports on BYSI. Zacks Investment Research downgraded shares of Beyondspring from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $41.00 target price on shares of Beyondspring in a research note on Wednesday, September 18th.

Beyondspring stock opened at $16.77 on Friday. The firm has a 50-day moving average of $18.26 and a 200-day moving average of $17.42. Beyondspring has a one year low of $13.06 and a one year high of $25.79. The company has a market cap of $385.00 million, a price-to-earnings ratio of -6.93 and a beta of 1.30.

Beyondspring (NASDAQ:BYSI) last issued its earnings results on Wednesday, September 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.05). Analysts expect that Beyondspring will post -1.54 earnings per share for the current year.

A number of large investors have recently modified their holdings of BYSI. Nisa Investment Advisors LLC bought a new stake in shares of Beyondspring during the 3rd quarter valued at $134,000. Vanguard Group Inc. bought a new stake in shares of Beyondspring in the 2nd quarter valued at $956,000. BlackRock Inc. bought a new stake in shares of Beyondspring in the 2nd quarter valued at $11,904,000. Northern Trust Corp bought a new stake in shares of Beyondspring in the 2nd quarter valued at $720,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Beyondspring in the 2nd quarter valued at $516,000. Institutional investors and hedge funds own 5.27% of the company’s stock.

About Beyondspring

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Featured Article: Quantitative Easing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.